Global CAR-T Therapy Market Size

Future Growth Forecast For The CAR-T Therapy Global Market 2023-2032

The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

  • Market Expansion: The global CAR-T therapy pipeline analysis market has witnessed substantial growth, surging from $1.8 billion in 2022 to $2.25 billion in 2023, marking a remarkable compound annual growth rate (CAGR) of 25.0%.
  • Future Projections: Anticipated growth continues, with the market size projected to reach $3.9 billion in 2027, maintaining a steady CAGR of 14.7%.

Driving Forces Behind CAR-T Therapy Market

  • Financial Support: A key driver of the CAR-T therapy market is the increasing financial support from various organizations dedicated to advancing CAR-T therapy development and accessibility.
  • Government Initiatives: Government and non-government organizations contribute financial support for both research and development by companies and the treatment of acute lymphoblastic leukemia (ALL) patients.
  • Exemplary Case: The University of California San Diego School of Medicine received a grant of US$ 4.1 million in December 2021 from the California Institute for Regenerative Medicine, further illustrating the financial backing driving CAR-T therapy development.

Key Players in the CAR-T Therapy Market

  • Market Leaders: Major players shaping the chimeric antigen receptor (CAR)-T therapy market include Novartis AG, Kite Pharma, Pfizer Inc., Juno Therapeutics, Celgene Corporation, CARsgen Therapeutics, Sorrento Therapeutics, Legend Biotech, Mustang Bio, and Immune Therapeutics.
  • Clinical Trials: Companies are actively conducting clinical trials to assess the effectiveness of CAR-T therapy in treating multiple myeloma, a type of white blood cell cancer that accumulates in the bone marrow.
  • Targeting Multiple Myeloma: CAR-T therapy is being explored as a treatment for relapsed or refractory multiple myeloma (RRMM), with Novartis introducing T-Charge™, a next-generation CAR-T platform, in December 2021.

Advancements in CAR-T Therapy

  • Next-Generation Platform: Novartis announced the introduction of T-Charge™ as a next-generation CAR-T platform, serving as the foundation for various investigational CAR-T cell therapies in their pipeline.
  • Early Clinical Stage: T-Charge™ was in the early clinical stage (Phase I), showcasing the ongoing commitment to advancing CAR-T therapy for multiple myeloma and other applications.

Market Segmentation
The global CAR-T therapy pipeline analysis market is comprehensively segmented to provide insights into its diverse landscape:

  1. By Type:
    • Monotherapy
    • Combination Therapy
  2. By Target Antigen:
    • CD19
    • CD22
    • Other Target Antigens
  3. By Application:
    • Acute Lymphoblastic Leukemia
    • Diffuse Large B-Cell Lymphoma
    • Follicular Lymphoma
    • Chronic Lymphocytic Leukemia
    • Multiple Myeloma
    • Other Applications

Regional Dynamics

  • North America Leadership: North America emerged as the largest region in the CAR-T therapy market in 2022, highlighting the region’s significant contribution to advancing and adopting this revolutionary cancer treatment.

View More On The CAR-T Therapy Market Report 2023 –

Request A Sample Of The Global CAR-T Therapy Market Report 2023:

The CAR-T Therapy Global Market Report 2023  provides a comprehensive overview on the CAR-T therapy market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Coronavirus (COVID-19) Current Therapy Global Market Report 2023
Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Global Market Report 2023
Bioinformatics Global Market Report 2023

Contact us at:
The Business Research Company:
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
Global Market Model: